Replies to post #201141 on Biotech Values

[DewDiligence]

I can't see why Shire wouldn't want generic Humira unless they feel that with dozens of other companies involved the competitive landscape is unfavorable.

SHPG doesn't have any FoB programs, so they may decide that M923 falls outside their scope of interest.